PTC Therapeutics and Novartis Sign $3 Billion Deal for Huntington's Disease Drug Development

The agreement grants Novartis global rights to PTC518, an experimental oral therapy, with PTC receiving $1 billion upfront and potential milestone payments.

• PTC Therapeutics has partnered with Novartis in a licensing deal worth up to $3 billion for the development and commercialization of PTC518, a potential treatment for Huntington's disease.
• PTC will receive $1 billion upfront and up to $1.9 billion in milestone payments, along with a 40% share of U.S. profits and double-digit royalties on ex-U.S. sales.
• PTC518, currently in Phase 2 trials, has shown promising interim results, including dose-dependent reductions in mutant Huntingtin protein and early clinical benefits after 12 months of treatment.
• Novartis will take over development, manufacturing, and commercialization of PTC518 following the expected completion of the Phase 2 trial in early 2025.
• PTC plans to use the proceeds from the deal to expand its splicing platform and advance its development and commercial portfolio.

3 Articles

Benzinga Investopedia GEN